Recuro Health Closes $47 Million Series B Financing Led by ARCH Venture Partners, Advancing Innovative Virtual-First Care Service

Recuro Health (Recuro), an integrated digital health solutions company designed to transition the U.S. healthcare system from a reactive, disease-focused model to a proactive care approach, today announces the closing of a $47 million Series B round investment.

The Series B syndicate includes both new and existing investors, including ARCH Venture Partners, the Flippen Group, GPG Ventures, 4D Capital and other investors.
Recuro Health will use the proceeds to advance and scale its Digital Medical Home, which includes diagnostic-enabled Virtual Primary Care and Virtual Behavioral Health Solutions that are tailored to fit the healthcare needs of any population. The Digital Medical Home care model integrates advanced science, data, at-home diagnostics and targeted genomics — cancer screening, pharmacogenomics – to better inform integrated care.

“The continued support of our investors is a clear sign of their confidence in our mission,” says Michael Gorton, CEO and founder, Recuro Health. “We have an extraordinary team at Recuro dedicated to evolving healthcare to be more proactive and personal, resulting in improved outcomes, better patient engagement and lower costs. In this next phase of our Company growth and expansion, we are committed to building upon the success of our Digital Medical Home and continuing to advance the next generation of digital care services.”

Recuro’s digital health solutions are currently available nationwide and used by millions of members.

Robert Nelsen, co-founder and managing director, ARCH Venture Partners, says, “Recuro is proving to be the best of breed in the intersection of science, diagnostics and digital health. This nimble organization has the ability to quickly respond to market changes, scale its tech-enabled services and close gaps in care that improve population health. We see significant opportunities for exceptional growth and continued success.”

Founded in 2021, Recuro Health has garnered industry recognition as a pioneer in developing innovative digital solutions that integrate Virtual Primary Care and Urgent Care, Behavioral Health, at-home lab testing, genomics as well as a suite of enabling capabilities such as care navigation, data analytics, quality and guided referrals.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.

By using this website you agree to accept Medical Device News Magazine Privacy Policy